SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending amid speculation about a potential short squeeze and renewed interest in privacy coins. Some community members are drawing comparisons to Bitcoin's early days, while others highlight its limited supply and upcoming halving event. The conversation includes discussion of potential price targets and whether ZEC can outperform other cryptocurrencies.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as community members highlight its strong ties to the Bitcoin network and its fair launch distribution. Discussion points include its potential for mainstream adoption and comparisons to other memecoins. The community emphasizes its organic growth and increasing recognition within the crypto space.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter (JUP) is trending as community members express bullish sentiment and analyze charts for potential double bottoms. There's also significant discussion around the meme coin $UPDOG, which is listed on Jupiter, with users highlighting its community and potential for becoming a millionaire. Additionally, Jupiter Lend and its features like high LTVs are being discussed.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to record October delivery numbers, marking a significant year-over-year increase that has the community buzzing with excitement. Investors are optimistic about NIO's growing ecosystem and potential for further expansion, particularly with its innovative battery-swapping technology. Community members are closely watching for continued growth and a potential turning point towards profitability.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

IMSR (Terrestrial Energy) is trending as investors discuss its potential in the nuclear energy sector, particularly in relation to powering AI data centers. Community members are comparing IMSR's valuation to peers like OKLO and SMR, with some believing it's undervalued and poised for significant growth. Discussions also involve the company's technology, government partnerships, and potential catalysts for a price surge.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor ($TAO) is gaining attention due to its role in decentralized AI, positioning itself as a competitor to centralized AI developers. Community members are focused on its upcoming halving event and potential institutional investment via an ETP. The community is also actively discussing staking yields and subnet developments within the Bittensor network.

Bounce Token

Bounce Token is trending as traders discuss its potential for significant gains, fueled by its relatively low supply and active development. Community members are pointing to its history of massive pumps, with some anticipating a run to previous highs. The conversation includes speculation on potential price targets and comparison to other low-cap coins.

SiriusXM Holdings, Inc. engages in the provision of audio entertainment. It operates through Sirius XM and Pandora and Off-Platform segments. The company was founded on May 17, 1990, and is headquartered in New York, NY.

Sirius XM Holdings Inc.

Sirius XM Holdings Inc

SIRI is trending due to recent earnings and speculation around future performance; community chatter involves whether Berkshire Hathaway will increase its stake or potentially buyout the company. Discussions also include the stock's low valuation, dividend yield, and potential for a short squeeze, with some concerned about competition from streaming services and debt levels, while others are excited about new content and insider buying.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending amid analyst upgrades and anticipation for upcoming earnings, with the community eyeing potential AI-related announcements. Bullish sentiment seems to be building as the stock approaches 52-week highs, while some traders debate the company's valuation. Chatter surrounds a possible acquisition of GitLab which could have impacts in the software space.

The Bank of Nova Scotia engages in the provision of financial products and services including personal, commercial, corporate, and investment banking. It operates through the following segments: Canadian Banking, International Banking, Global Wealth Management, Global Banking and Markets, and Other. The company was founded on March 30, 1832 and is headquartered in Toronto, Canada.

Bank Of Nova Scotia

BNS is trending amid discussions about its strategic direction, including workforce cuts aimed at cost efficiency and the launch of a modernized U.S. Cash Management platform. Community members are analyzing its valuation, dividend yield, and exposure to Latin American markets, with some expressing frustration over the stock's performance relative to its peers and earnings potential. Analysts are weighing in with mixed opinions and updated price targets, factoring in both the bank's challenges and opportunities for growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Emergent Biosolutions Inc. (EBS) Soars to 52-Week High, Time to Cash Out?

Emergent Biosolutions (EBS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

<ul class="summary-bullets"><li>Shares of Emergent BioSolutions jumped 18% in after-hours trading after the company posted stronger-than-expected Q3 results and raised its full-year guidance.</li><li>The quarter saw double-digit revenue growth led by Narcan and smallpox vaccine sales, along with margin gains and lower operating costs.</li><li>On Stocktwits, retail traders turned upbeat, with some predicting further upside in the coming sessions.</li></ul>Emergent BioSolutions shares rallied 18% in after-hours trading on Wednesday, sparking a wave of retail chatter on Thursday. The biotech firm surprised Wall Street with better-than-expected third-quarter (Q3) results, raised its 2025 outlook, and showed real traction across its naloxone and biodefense product lines.<h2 class="st-heading-2">Revenue Tops Forecast, Margins Improve</h2>Emergent delivered Q3 revenue of $231 million, up 10% from last year and ahead of guidance, helped by strong sales of its Narcan nasal spray and new government contracts for smallpox and anthrax countermeasures. Gross margin improved to 57%, while the company held costs in check, and operating expenses fell 41% from a year ago.Net income came in at $51 million, a big turnaround from last year’s losses, as Emergent’s restructuring efforts and product mix paid off. The company also reduced its net debt by nearly 20% and ended the quarter with $346 million in liquidity, including $246 million in cash.The company raised full-year revenue guidance to $775–$835 million and lifted adjusted EBITDA expectations to $195–$210 million, citing solid execution and international demand.<h2 class="st-heading-2">Smallpox Demand Drives Upside</h2>Emergent said its Narcan and Kloxxado products continue to lead the naloxone market, benefiting from stable U.S. pricing and growing over-the-counter availability. Meanwhile, international sales made up 34% of total medical countermeasure revenue and are proving more profitable than U.S. contracts.Sales of the company’s smallpox vaccine climbed 15% year over year, supported by long-term global supply deals. Emergent also highlighted progress on its partnership with Switzerland’s Rocketvax, with the first clinical trial for a next-generation vaccine platform expected to start in early 2026.<h2 class="st-heading-2">Stocktwits Traders See More Upside Ahead</h2>On Stocktwits, retail sentiment for Emergent BioSolutions shifted to ‘extremely bullish’ from ‘neutral’ a day ago amid a 289% jump in 24-hour message volume.&nbsp;One user predicted that Emergent BioSolutions’ stock could open around $20 or higher, saying they wouldn’t be surprised by a sharp move up.<stembedurl>https://stocktwits.com/angelburgosg/message/634258031</stembedurl>Another commenter said they viewed Emergent as a $30 stock, even without a potential buyout, adding that short sellers might soon be forced to cover.<stembedurl>https://stocktwits.com/Kawasaki1/message/634257787</stembedurl><a href="https://stocktwits.com/symbol/EBS">Emergent BioSolutions’ stock</a> has declined 2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The exterior view of the Emergent BioSolutions plant on April 01, 2021 in Baltimore, Maryland. (Photo by Tasos Katopodis/Getty Images)

Retail Traders Turn Ultra-Bullish On Emergent BioSolutions After Surprise Q3 Profit

Shares of Emergent BioSolutions jumped 18% in after-hours trading after the company posted stronger-than-expected Q3 results and raised its full-year guidance.

Equity

Emergent Biosolutions (EBS) Beats Q3 Earnings and Revenue Estimates

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of +983.33% and +20.88%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

After a low period, biotech stocks are on the upswing, experts say

After a period of weakness, biotech stocks are on the upswing, experts say. But bear in mind: Putting your money into biotechnology companies can lead you on something of a wild ride.The field, which...

Emergent BioSolutions Inc. (EBS) on Friday said that it has secured new purchase orders from an international government partner for a multiproduct supply agreement.The agreement is valued at $29 million, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-29-million-mcm-product-orders">said</a>. The order encompasses several product offerings within Emergent’s medical countermeasures business, including countermeasures for threats posed by Smallpox, Anthrax, and Botulism. The company said that this is the second procurement made by the same government this year.Shares of the company jumped 3% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/EBS">EBS stock</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:575/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_19_at_11_37_08_AM_png_46c276596d.webp" alt="EBS's Sentiment Meter and Message Volume as of 11:37 a.m. ET on Sept. 19, 2025 | Source: Stocktwits" width="575" height="61"><figcaption>EBS's Sentiment Meter and Message Volume as of 11:37 a.m. ET on Sept. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock is “significantly undervalued,” while indicating that they see more than 100% upside.<stembedurl>https://stocktwits.com/NRG8/message/629302236</stembedurl>Another user expects the stock to hit $10 next week.<stembedurl>https://stocktwits.com/shoagh12/message/629291934</stembedurl>Emergent said it will receive about $26 million in 2025 under the agreement. This is in addition to more than $100 million in sales already generated for the company’s MCM portfolio outside the U.S. so far this year, it said.“Together with demand from the U.S. government, these international procurements reinforce the potential for our growth trajectory as part of Emergent’s multi-year transformation plan and highlights the strength of Emergent’s global footprint,” CEO Joe Papa said. The CEO also added that the company continues to see countries elevating their investment in defense preparedness.Emergent delivers solutions for health threats like Smallpox, Mpox, Botulism, Ebola, Anthrax, and Opioid overdose emergencies.Earlier this week, the company also announced that it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA) to supply Tembexa oral suspension. At the start of the month, the company also announced that a contract modification had been executed for $56 million to supply ACAM2000, a live vaccinia virus vaccine approved by the FDA for use in preventing Smallpox and Mpox in individuals at high risk of infection, to the U.S. government.EBS stock is down 14% this year but up approximately 17% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paramount-skydance-likely-preparing-22to24-per-share-bid-for-warner-bros-discovery/chD34ulR3Ta">Paramount Skydance Likely Preparing $22 To $24 Per Share Bid For Warner Bros. Discovery: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the Emergent BioSolutions logo of an US biopharmaceutical company is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Emergent BioSolutions Stock Rises After Receiving Fresh International Purchase Orders: Retail Says Stock Is ‘Significantly Undervalued’

The order encompasses multiple product offerings within Emergent’s medical countermeasures business, including countermeasures for threats posed by Smallpox, Anthrax, and Botulism.

Emergent BioSolutions shares rose after the company disclosed that it will supply additional doses of CNJ-016, a treatment used for certain complications of the smallpox vaccine, to the U.S. government.The company’s shares closed 3.8% higher at $6.87 on Tuesday, with shares rising another 3.5% to $7.11 in after-hours trading.The new shipment is part of a long-term deal signed back in 2019 with the Administration for Strategic Preparedness and Response, a branch of the Department of Health and Human Services.&nbsp;CNJ-016 is used to treat uncommon but serious side effects from the smallpox vaccine, such as eczema vaccinatum and progressive vaccinia.&nbsp;It is not intended for&nbsp;the treatment of postvaccinal encephalitis or isolated vaccinia keratitis.&nbsp;The product comes with several safety considerations, including risks of allergic reactions, kidney issues, blood clots, and inaccurate blood sugar readings in some patients due to interference with glucose monitors.This latest modification comes shortly after a separate $62.4 million award on June 23, also from ASPR, for additional supply of Emergent’s botulism antitoxin, BAT.&nbsp;The BAT treatment is used in confirmed or suspected cases of botulism involving multiple neurotoxin types.In a separate update last week, the company expanded its NARCANDirect platform to include Kloxxado Nasal Spray 8 mg, an opioid overdose reversal medication.&nbsp;The online ordering system is available to groups, including first responders, schools, government agencies, and community-based programs focused on naloxone distribution.On Stocktwits, retail sentiment was ‘neutral’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/EBS">Emergent BioSolutions’ stock</a> has risen 33.1% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Emergent BioSolutions Stock Rises After New US Order For Smallpox Complication Therapy

The company also secured a $62.4 million modification to its botulism antitoxin supply contract and recently expanded its NARCANDirect platform to include a new opioid overdose reversal spray.

5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost

Zacks.com featured highlights include BrightSpring Health Services, Beyond, Air Canada, HF Sinclair and Emergent BioSolutions

Emergent Biosolutions (EBS) Q1 Earnings Top Estimates

Shares of Emergent BioSolutions plunged more than 8% in after-hours trading on Monday after the company reported a steep revenue drop in the fourth quarter.&nbsp;While Emergent swung to a profit, the earnings beat failed to offset concerns over its shrinking top line.The medical contract development and manufacturing firm posted adjusted net income of $0.05 per diluted share, a sharp reversal from the $0.77 per share loss a year earlier. Analysts had expected a loss of $0.43 per share.&nbsp;However, quarterly revenue fell to $194.7 million from $276.6 million a year ago, well below the consensus estimate of $249.5 million.For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.&nbsp;For 2025, the company projected revenue of $750 million to $850 million, significantly trailing the $1.11 billion analysts had expected.“We delivered favorable full-year financial results driven by our core products, all the while completing a series of strategic stabilization actions to strengthen our financial position ahead of plan,” CEO Joe Papa said.&nbsp;“This strong foundation enables Emergent to focus on profitable revenue growth and cash generation as we move forward with turnaround activities, a critical phase in our multi-year transformation plan.”Despite the revenue shortfall, retail traders on Stocktwits remained optimistic, with sentiment for EBS ending Monday in the ‘bullish’ zone.&nbsp;Many users focused on the company’s improving profitability rather than its shrinking revenue.&nbsp;One trader compared the current situation to a period before Emergent had its Narcan opioid overdose nasal spray in its portfolio, arguing that profitability was the key factor.<stembedurl>https://stocktwits.com/WinstonSmith33/message/606629996</stembedurl>Another user pointed to CEO Joe Papa’s comments on the earnings call, noting that the company’s 2025 guidance appeared “conservative.”&nbsp;<stembedurl>https://stocktwits.com/GrantDiaz/message/606587312</stembedurl>Some traders speculated that Emergent’s mpox vaccine sales had not yet been factored into the guidance.&nbsp;While the company’s smallpox vaccine has been used for mpox, it has not yet&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/govx-siga-ebs-cmrx-stocks-gain-who-declares-who-public-health-emergency/cJId4JgRge">received</a> formal FDA approval for that indication.<a href="https://stocktwits.com/symbol/EBS">Emergent BioSolutions shares</a> are down more than 28% year-to-date but have more than doubled over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 30%, But Retail Clings To Profit Swing

For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.

Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 40%, But Retail Clings To Profit Swing

For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.


Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.38	--	--	N/A
Q3 '25	-$0.07	$1.06	1689.99%	BEAT
Q2 '25	-$0.41	$0.16	138.71%	BEAT
Q1 '25	$0.44	$0.71	61.36%	BEAT
Q4 '24	-$0.43	$0.05	111.63%	BEAT

EBS
Emergent Biosolutions Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest EBS News

EBSEmergent Biosolutions Inc